Evidence map›Paper›PMID 39617334›Full record

ArticleDiabetes research and clinical practice2025

High one-hour plasma glucose is an intermediate risk state and an early predictor of type 2 diabetes in a longitudinal Korean cohort.

Myungsoo Im, Jinmi Kim, Soree Ryang, Doohwa Kim, Wook Yi, Jeong Mi Kim, Minsoo Kim, Yeong Jin Kim, Young Jin Kim, Hyuk Kang and 7 more

Abstract read
In one paragraph

Article in Diabetes research and clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Myungsoo ImDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Jinmi KimBiomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; Department of Biostatistics, Clinical Trial Center, Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Soree RyangDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Doohwa KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Wook YiDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
Jeong Mi KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
Minsoo KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
Yeong Jin KimBiomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea.
Young Jin KimCenter for Global R&D Data Analysis, Division of Data Analysis, Korea Institute of Science and Technology Information (KISTI), Seoul, Republic of Korea.
Hyuk KangDivision of Fundamental Research On Public Agenda, National Institute for Mathematical Sciences, Daejeon, Republic of Korea.
In Joo KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea.
Ram JagannathanHubert Department of Global Health, Emory University School of Public Health Atlanta, GA, USA.
Stephanie T ChungSection on Pediatric Diabetes, Obesity, and Metabolism, Diabetes, Endocrinology, and Obesity Branch, National Institute of Diabetes, Digestive and Kidney Disease, National Institutes of Health, Bethesda, MD, USA.
Michael BergmanNYU Grossman School of Medicine, Holman Division of Endocrinology, Diabetes and Metabolism, VA New York Harbor Healthcare System, New York, NY, USA.
Arthur S ShermanLaboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Sang Soo KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea; Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea; Department of Internal Medicine, Pusan National University School of Medicine, Yangsan, Republic of Korea. Electronic address: drsskim7@gmail.com.
Joon HaDepartment of Mathematics, Howard University, Washington DC, USA. Electronic address: joon.ha@howard.edu.

Funding

Modeling Pathogenesis of Type 2 DiabetesZIADK075137 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SHERMAN, ARTHUR · 2016 to 2025
$3.3M
Intramural NIH HHS ZIA DK075137
6 · The paper itself

Abstract

aimsBecause one-hour post-load plasma glucose (1h-PG) ≥ 155 mg/dL (8.6 mmol/L) has been proposed as an early marker for future diabetes but lacks sufficient longitudinal confirmation of its risk, we aimed to evaluate the risk of T2D based on 1h-PG and track changes of insulin sensitivity and β-cell function over time by 1h-PG in a longitudinal cohort.

methodsOGTTs were conducted every 2 years in the 10-year longitudinal Korean Genome Epidemiology study (n = 6144) with three groups characterized at baseline: Low 1h-PG (< 155 mg/dL) with Normal Glucose Tolerance (NGT), High 1h-PG (≥155 mg/dL) with NGT, and prediabetes (PreDM).

resultsT2D risk was higher in people with High 1h-PG with NGT and PreDM than those with Low 1h-PG with NGT. Baseline insulin sensitivity in Low 1h-PG as measured by the insulin sensitivity and secretion (ISS) model and Matsuda insulin sensitivity index (ISI) was higher than in High 1h-PG, which was comparable to PreDM. β-cell function as assessed by ISS and the insulinogenic index decreased from Low 1h-PG to High 1h-PG to PreDM. Over time, insulin sensitivity decreased in the three groups. Time from High 1h-PG to T2D was 0.9 years shorter than from Low 1h-PG. All participants passed the 1h-PG threshold for T2D (209 mg/dL, 11.6 mmol/L) first, and 74 % passed the 1h-PG threshold for impaired glucose tolerance (IGT; 155 mg/dL) first.

conclusionsHigh 1h-PG NGT is an intermediate risk category between Low 1h-PG NGT and PreDM and may provide an opportunity for early intervention to prese rve ß-cell function.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2Prediabetic StateAdultFemaleGlucose Tolerance TestHumansInsulin ResistanceInsulin-Secreting CellsLongitudinal StudiesMaleMiddle AgedRepublic of KoreaRisk FactorsBlood GlucoseBeta-cell functionInsulin sensitivityOne-hour plasma glucosePrediabetesType 2 diabetes

Identifiers

PMID39617334
PMCPMC13634366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.